FI3914247T3 - Migalostaatin käyttö alennettaessa aivoverisuonitapahtuman riskiä potilaissa, joilla on fabryn tauti - Google Patents
Migalostaatin käyttö alennettaessa aivoverisuonitapahtuman riskiä potilaissa, joilla on fabryn tauti Download PDFInfo
- Publication number
- FI3914247T3 FI3914247T3 FIEP20708283.5T FI20708283T FI3914247T3 FI 3914247 T3 FI3914247 T3 FI 3914247T3 FI 20708283 T FI20708283 T FI 20708283T FI 3914247 T3 FI3914247 T3 FI 3914247T3
- Authority
- FI
- Finland
- Prior art keywords
- migalastat
- salt
- use according
- patient
- event
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795524P | 2019-01-22 | 2019-01-22 | |
| PCT/US2020/014531 WO2020154354A1 (en) | 2019-01-22 | 2020-01-22 | Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3914247T3 true FI3914247T3 (fi) | 2025-02-16 |
Family
ID=69726736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20708283.5T FI3914247T3 (fi) | 2019-01-22 | 2020-01-22 | Migalostaatin käyttö alennettaessa aivoverisuonitapahtuman riskiä potilaissa, joilla on fabryn tauti |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220087993A1 (https=) |
| EP (2) | EP4523750A3 (https=) |
| JP (2) | JP7680356B2 (https=) |
| AR (1) | AR117861A1 (https=) |
| DK (1) | DK3914247T3 (https=) |
| ES (1) | ES3007212T3 (https=) |
| FI (1) | FI3914247T3 (https=) |
| HR (1) | HRP20250078T1 (https=) |
| HU (1) | HUE069934T2 (https=) |
| LT (1) | LT3914247T (https=) |
| PL (1) | PL3914247T3 (https=) |
| PT (1) | PT3914247T (https=) |
| RS (1) | RS66410B1 (https=) |
| SI (1) | SI3914247T1 (https=) |
| SM (1) | SMT202500034T1 (https=) |
| TW (1) | TW202042812A (https=) |
| WO (1) | WO2020154354A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12594268B2 (en) * | 2018-08-20 | 2026-04-07 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| MX2009010557A (es) | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| US9999618B2 (en) * | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| EP2946785B1 (en) | 2008-02-12 | 2018-10-24 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| TW202408513A (zh) * | 2016-07-19 | 2024-03-01 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
-
2020
- 2020-01-20 TW TW109101869A patent/TW202042812A/zh unknown
- 2020-01-22 PL PL20708283.5T patent/PL3914247T3/pl unknown
- 2020-01-22 HU HUE20708283A patent/HUE069934T2/hu unknown
- 2020-01-22 ES ES20708283T patent/ES3007212T3/es active Active
- 2020-01-22 AR ARP200100155A patent/AR117861A1/es unknown
- 2020-01-22 US US17/424,979 patent/US20220087993A1/en active Pending
- 2020-01-22 EP EP24212005.3A patent/EP4523750A3/en active Pending
- 2020-01-22 PT PT207082835T patent/PT3914247T/pt unknown
- 2020-01-22 EP EP20708283.5A patent/EP3914247B1/en active Active
- 2020-01-22 RS RS20250066A patent/RS66410B1/sr unknown
- 2020-01-22 FI FIEP20708283.5T patent/FI3914247T3/fi active
- 2020-01-22 JP JP2021542102A patent/JP7680356B2/ja active Active
- 2020-01-22 DK DK20708283.5T patent/DK3914247T3/da active
- 2020-01-22 SI SI202030569T patent/SI3914247T1/sl unknown
- 2020-01-22 LT LTEPPCT/US2020/014531T patent/LT3914247T/lt unknown
- 2020-01-22 HR HRP20250078TT patent/HRP20250078T1/hr unknown
- 2020-01-22 SM SM20250034T patent/SMT202500034T1/it unknown
- 2020-01-22 WO PCT/US2020/014531 patent/WO2020154354A1/en not_active Ceased
-
2025
- 2025-05-08 JP JP2025077689A patent/JP2025128105A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3914247T (pt) | 2025-01-23 |
| PL3914247T3 (pl) | 2025-04-14 |
| EP3914247B1 (en) | 2024-11-13 |
| ES3007212T3 (en) | 2025-03-19 |
| RS66410B1 (sr) | 2025-02-28 |
| LT3914247T (lt) | 2025-01-27 |
| SI3914247T1 (sl) | 2025-03-31 |
| HRP20250078T1 (hr) | 2025-03-28 |
| DK3914247T3 (da) | 2025-01-27 |
| SMT202500034T1 (it) | 2025-03-12 |
| HUE069934T2 (hu) | 2025-04-28 |
| EP3914247A1 (en) | 2021-12-01 |
| WO2020154354A1 (en) | 2020-07-30 |
| JP2022518733A (ja) | 2022-03-16 |
| EP4523750A3 (en) | 2025-06-11 |
| JP2025128105A (ja) | 2025-09-02 |
| US20220087993A1 (en) | 2022-03-24 |
| TW202042812A (zh) | 2020-12-01 |
| AR117861A1 (es) | 2021-09-01 |
| JP7680356B2 (ja) | 2025-05-20 |
| EP4523750A2 (en) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11865098B1 (en) | Methods and compositions for treating excessive sleepiness | |
| ES2532849T5 (es) | Tratamiento con agonista de la melatonina | |
| Brodie et al. | Zonisamide: its pharmacology, efficacy and safety in clinical trials | |
| KR20100014392A (ko) | 섬유근통 치료용 드록시도파 및 약학 조성물 | |
| CN102573823B (zh) | 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途 | |
| JP6619744B2 (ja) | 神経障害の処置のためのバクロフェン、アカンプロセート、及び中鎖トリグリセライドの併用 | |
| IL310648A (en) | Methods for increasing and/or stabilizing cardiac functions in patients with Fabry disease | |
| MX2023001014A (es) | Composiciones farmaceuticas que comprenden venglustat. | |
| FI3914247T3 (fi) | Migalostaatin käyttö alennettaessa aivoverisuonitapahtuman riskiä potilaissa, joilla on fabryn tauti | |
| CA2898619C (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MD3697399T2 (ro) | Agenți terapeutici pentru utilizare în tratamentul sindromului picioarelor neliniștite | |
| JP2022518733A5 (https=) | ||
| ES2668943T3 (es) | Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz | |
| CA2612179A1 (en) | A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion | |
| Range et al. | DONEPEZIL (continued) | |
| Kishimoto et al. | Reply to: acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamine | |
| Bertek | New molecular entities | |
| JPS61145119A (ja) | 脳障害による精神症状の改善，治療剤 | |
| Dumbrava et al. | USE OF A RIVASTIGMINE TRANSDERMIC PATCH IN ALZHEIMER’S DISEASE AND PARKINSON’S DISEASE DEMENTIA | |
| RU2008100280A (ru) | Новая фармацевтическая композиция и ее применение в способе лечения пациентов с гиперемией и отеком слизистой оболочки верхних дыхательных путей | |
| NZ623255B2 (en) | Methods for treating a stroke-related sensorimotor impairment using aminopyridines | |
| HK1138500A (en) | Use of dimiracetam in the treatment of chronic pain | |
| CN102526088A (zh) | 维生素b12口服制剂的改进配方及用途 |